Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2007 Dec;31(12):2370-7.
doi: 10.1007/s00268-007-9245-6.

Is preoperative transarterial chemoembolization needed for a resectable hepatocellular carcinoma?

Affiliations
Comparative Study

Is preoperative transarterial chemoembolization needed for a resectable hepatocellular carcinoma?

Gi-Hong Choi et al. World J Surg. 2007 Dec.

Abstract

Background: Whether preoperative transarterial chemoembolization (TACE) has the therapeutic benefits in patients with resectable hepatocellular carcinoma (HCC) remains uncertain.

Materials and methods: We retrospectively investigated the influence of preoperative TACE on both disease-free survival and the pattern of recurrence after curative resection. From March 1998 to January 2005, a series of 273 patients who underwent curative resection for HCC were reviewed. Altogether, 120 patients underwent preoperative TACE, and 153 patients did not. We compared disease-free survival and the recurrence patterns between TACE and non-TACE groups, as well as between subgroups, stratified with regard to initial tumor size (< or =3 cm, 3-5 cm, >5 cm) and pathologic tumor stage (stage I-II and stage III-IVa). We also compared disease-free survival and the pattern of recurrence among the three groups: complete necrosis, incomplete necrosis, non-TACE groups.

Results: The 1-, 3-, and 5-year disease-free survival rates were 76.0%, 57.7%, and 51.3%, respectively, in the TACE group and 70.9%, 53.8%, and 46.8%, respectively, in the non-TACE group. No significant difference was observed in disease-free survival or the pattern of recurrence between the TACE and non-TACE groups. Further analysis of disease-free survival and the pattern of recurrence between subgroups according to initial tumor size and tumor stage showed no significant differences. Complete necrosis of tumor was recognized in only 33 patients of the TACE group (p = 0.001). Among the three complete necrosis, incomplete necrosis, and non-TACE groups, no significant difference was observed in disease-free survival or the pattern of recurrence.

Conclusions: Preoperative TACE did not significantly improve the disease-free survival or the pattern of recurrence after curative resection of HCC. Even though this study is a retrospective analysis, preoperative TACE cannot be recommended as a routine procedure before hepatectomy for a resectable HCC.

PubMed Disclaimer

References

    1. Eur J Surg Oncol. 2006 Sep;32(7):773-9 - PubMed
    1. Hepatogastroenterology. 2003 May-Jun;50(51):750-5 - PubMed
    1. Hepatology. 2003 Feb;37(2):429-42 - PubMed
    1. World J Surg. 1996 Mar-Apr;20(3):326-31 - PubMed
    1. Ann Surg. 1996 Jul;224(1):4-9 - PubMed

Publication types

LinkOut - more resources